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ASSESSMENT OF LUNG FUNCTION BEFORE AND AFTER ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION IN A SINGLE PEDIATRIC
CENTER
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Background: Allogeneic hematopoietic stem cell transplantation
(aHSCT) is being used with increasing success in pediatric patients
to treat a variety of malignant and non-malignant diseases. However,
pulmonary complications account for meaningful morbidity and
mortality in aHSCT recipients.
Objective: We assessed the prevalence of pre and post-aHSCT
lung function abnormalities at Riley Hospital for Children to
identify risk factors that may predict post-aHSCT morbidity and
mortality.
Methods: We retrospectively reviewed the medical records of 46
patients, aged 5–21 years, who received aHSCT between 1 January
2001 and 31 December 2006. Forty-one patients, who underwent
pulmonary function tests (PFTs) both before and after aHSCT,
were eligible for analysis. Pertinent demographic, aHSCT and
treatment-related data, and baseline (pre-aHSCT), 1 and 2-year
post-aHSCT PFT data were collected. Forced expiratory volume
in 1 second (FEV1), forced vital capacity (FVC), residual volume
(RV), total lung capacity (TLC), and diffusion capacity for carbon
monoxide adjusted for alveolar volume and hemoglobin (DLCOa/
VA) were determined as percentage predicted for age, sex, and
length matched controls. Analyses included logistic regression,
with and without generalized estimating equations, and mixed
effects models.
Results: Significantly lower FEV1, FVC, TLC, but similar
FEV1/FVC was noted at 1 year post-aHSCT. However, these find-
ings were no longer significant at 2 years post-aHSCT. Low base-
line DLCOa/VA was associated with death. Refractory disease
before aHSCT was significantly associated with lower FEV1,
FVC, and TLC after aHSCT. Age, CMV status, previous pulmo-
nary-toxic chemotherapy, and aHSCT conditioning were not sig-
nificantly associated with outcomes. Acute and chronic graft
versus host disease (GVHD) was significantly associated with
higher post-aHSCT RV.
Conclusions: Obstructive lung patterns contribute to post-
aHSCT morbidity, especially in the first year following aHSCT.
Low baseline DLCOa/VA was a risk factor for mortality. Pediatric pa-
tients who have evidence of acute and chronic GVHD are more
likely to have associated obstructive lung disease which suggests
that therapeutic intervention may prevent morbidity. Further
prospective studies are needed to assess the utility of long-term respi-
ratory monitoring in pediatric aHSCT recipients.224
MATCHED UNRELATED BONE MARROW TRANSPLANT FOR OMENN SYN-
DROME
Nahum, A., Reid, B., Grunebaum, E., Roifman, C.M. The Hospital for
Sick Children
Little information is currently available on the outcome and the
long term restoration of immune function in infants with Omenn
syndrome (OS) treated with bone marrow transplantation (BMT).
We prospectively followed patients with OS who received matched
unrelated donor bone marrow transplantation at our center. En-
graftment, immune reconstitution and transplant-related complica-
tions were recorded. Humoral and cellular immunity were
evaluated. Six patients with OS were diagnosed at a mean age of
4.6 months. Two had mutations in the RMRP gene, one had mu-
tations in DNA Ligase 4, while the rest genotype could not be de-
termined. They received a matched unrelated donor bone marrowtransplantation as the first BMT at the mean age of 9.4 months. All
six patients are alive and well at a mean 95 months after transplant.
All patients have evidence of full hemopoetic engraftment and ro-
bust immune reconstitution. Three out of six patients developed
GvHD of Grade II or more, which was reversed in all patients
by using short courses of high dose methylprednisolone. We
have shown here that matched unrelated donor bone marrow trans-
plantation is highly effective in curing patients with Omenn syn-
drome regardless of their genotype. This mode of treatment
should be preferred for patients with OS when a related identical
donor is not available.225
RELATIONSHIP BETWEEN ACETAMINOPHEN DOSAGE AND DEVELOP-
MENT OF ORGAN DYSFUNCTION DURING PEDIATRIC HEMATOPOETIC
STEM CELL TRANSPLANT
McArthur, J.A.1, Mikhailov, T.1, Rothchild, C.1, Talano, J.A.2 1Medical
College ofWisconsin,Milwaukee,WI; 2Medical College ofWisconsin,Mil-
waukee, WI
Background: Patients undergoing chemotherapy and radiation
have been shown to be in a state of oxidative stress. Acetaminophen
is known to cause depletion of glutathione, a key component of the
body’s antioxidant defense mechanism. Acetaminophen is also
known to cause liver toxicity and recently has been linked with sever-
ity of lung disease in asthmatics and alcoholics. Therefore, we ques-
tioned whether acetaminophen usage in patients undergoing
hematopoetic stem cell transplant (HSCT) could place them at
risk for organ dysfunction.
Methods: A retrospective chart review was performed on all pa-
tients undergoing HSCT at the Children’s Hospital of Wisconsin
between January 1, 1995–January 1, 2005. Cumulative dosage of
acetaminophen in mg/ kg was calculated on all patients during con-
ditioning and the first 14 days after stem cell infusion. Charts were
reviewed for evidence of veno-occlusive disease (VOD) of the liver
as diagnosed by the attending HSCT physician, respiratory insuffi-
ciency as defined by requirement of $2 l/min of nasal cannula oxy-
gen, and renal insufficiency as defined by doubling of the serum
creatinine. Statistical analysis was done using the unpaired student
t-test.
Results: Preliminary analysis found 330 patients who underwent
HSCT during the study time period. There was a statistically signif-
icant difference in the mean acetaminophen dose used in patient who
developed VOD (303 mg/kg) in comparison to those who did not
(213 mg/kg) with p5 .036. The difference in acetaminophen dosage
between those who developed renal insufficiency (278mg/kg) com-
pared to those who did not (210 mg/kg) was also significant (p 5
.028). The most significant difference was seen when comparing
patients who did (277 mg/kg) and did not (202 mg/kg) develop respi-
ratory insufficiency (p 5 .0019). Also of interest in our data set was
that of the 80 patients who developed respiratory insufficiency (re-
quirement of $2 l/min nasal cannula oxygen), 55 (69%) went on
to require some form of mechanical ventilation. The relative risk
of death in this population was 2.04 (95% CI 1.70–2.45).
Conclusion: This patient population is highly complex with mul-
tiple confounding variables. It is still unclear if acetaminophen is
a cause or marker of severity of illness in pediatric HSCT patients.
However, avoidance of frequent acetaminophen dosing may be ben-
eficial whenever possible.226
T-CELLS REDIRECTED AGAINST NKG2D-LIGANDS FOR THE IMMUNO-
THERAPY OF OSTEOSARCOMA
Kakarla, S.1,2, Shaffer, D.1,2, Ahmed, N.1,2, Wang, L.L.2, Lee, D.A.3,
Sentman, C.L.4, Gottschalk, S.1,2 1Baylor College of Medicine, Houston,
TX; 2Baylor College of Medicine, Houston, TX; 3University of Texas,
MDAnderson Cancer Center, Houston, TX; 4DartmouthMedical School,
Lebanon, NH
Background: Osteosarcoma is the most common pediatric bone
tumor. Despite aggressive multimodal therapy survival rates for pa-
tients with metastatic or recurrent disease remain poor. New
Poster Session-I 83targeted therapies are thus needed to improve outcomes and immu-
notherapy has the potentials to fulfill this need. We have previously
shown that genetically modified T cells expressing a chimeric anti-
gen receptor (CAR) composed of NKG2D and the CD3-z chain
have potent antitumor activity against several adult malignancies.
Since at present only limited targets are available for the immuno-
therapy of osteosarcoma, the aim of this study was to determine if
NKG2D-ligands (NKG2D-L) are expressed on the cell surface of
osteosarcoma and if NKG2D-L-specific T cells recognize and kill
osteosarcoma.
Methods and Results: NKG2D-L expression was determined by
FACS analysis as well as RT-PCR. 7 out of 8 cell lines tested
expressed one or several NKG2D-L on their cell surface.
NKG2D-L-specific T cells were generated by transducing CD3/
CD28-activated T cells with a SFG retroviral vector encoding the
NKG2D-L-specific CAR and truncated CD19 to allow detection
of transduced T cells. NKG2D-L-specific T cells from healthy
donors produced IFN-g in contrast to mock transduced T cells after
coculture with NKG2D-L-positive osteosarcoma cells. In cytotoxic-
ity assays, NKG2D-L-specific T cells killed NKG2D-L-positive
osteosarcoma cells where as activated, autologous lymphocytes and
NKG2D-L-negatvie osteosarcoma cells were not killed.
Conclusion: We have shown that NKG2D ligands are expressed
on osteosarcoma and that NKG2D-L specific T cells recognize and
kill osteosarcoma. Murine xenograft studies are in progress to con-
firm these findings in vivo. Adoptive immunotherapy with
NKG2D-L-specific T cells may represent a promising immunother-
apeutic approach for osteosarcoma.SOLID TUMORS
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CCR2B-TRANSDUCED CYTOTOXIC T LYMPHOCYTES SHOW ENHANCED
HOMING IN VIVO TOWARD CCL2-SECRETING NEUROBLASTOMA:
IMPLICATIONS FOR ENHANCED ADOPTIVE IMMUNOTHERAPY
Craddock, J.A., Lu, A., Rooney, C.M., Foster, A.E. Baylor College of
Medicine, Houston, TX
The chemokine CCL2 (MCP-1) is produced by a variety of can-
cers including neuroblastoma, melanoma, breast cancer and hemato-
logical malignancies. However, cytotoxic T lymphocytes (CTL)
used in clinical trials to treat these diseases do not express CCR2,
the receptor for CCL2. This deficiency may contribute to subopti-
mal trafficking to tumor sites and reduced clinical efficacy. There-
fore, we examined whether genetically modifying CTL with CCR2
could increase their homing towards tumor cells that produced
CCL2. CTL were first examined by flow cytometry for chemokine
receptor expression using antibodies to CCR2, CCR4, CCR5,
CCR7 and CXCR4. These CTL showed nominal expression
of CCR2 (\1%), low expression of CCR4 (10%), CXCR4 (25%),
CCR7 (5%), and high expression of CCR5 (70%). ELISA for
CCL2 was performed on established neuroblastoma cell lines
(IMR-32, LAN-1, SK-N-SH, JF) and on neuroblastoma cell lines
derived from patients primary tumors. All neuroblastoma cell lines
secreted CCL2 in variation but notably, all patient-derived primary
tumor cell lines secreted high levels of CCL2. T cells were activated
by anti-CD3/anti-CD28 antibody stimulation for 3 days in the pres-
ence of IL-2, and then transduced using a CCR2b retroviral vector.
Expression of CCR2b was detected by flow cytometry producing up
to 78% transduction. In vitro chemotaxis of CCR2b-transduced T
cells showed enhance migration to soluble CCL2 (.3 fold) as well
as to supernatants from CCL2-secreting cell lines (.2 fold) com-
pared to non-transduced T cells. To study in vivo migration, we
co-transduced T cells with EGFPluciferase and CCR2b. Subsequent
tail vein infusion of these co-transduced T cells into mice bearing
CCL2 secreting tumors (SK-N-SH) showed preferential migration
of only CCR2b-transduced T cells toward the tumor site when com-
pared to non-transduced T cells. These results demonstrate the fea-
sibility of influencing the trafficking of adoptively transferred T cells
toward CCL2 secreting neuroblastoma and thereby suggesting a po-
tential means to enhance future adoptive immunotherapies targeting
neuroblastoma.228
HIGH DOSE CHEMOTHERAPY WITH BLOOD OR MARROW TRANSPLANT
FOR RHABDOMYOSARCOMA: A CIBMTR ANALYSIS
Stiff, P., Agovi, M.-A., Antman, K., Camitta, B., Cairo, M., Childs, R.,
Edwards, J.R., Gale, R.P., Hale, G., Horowitz, M.M., Lazarus, H.,
Arora, M. CIBMTR, Milwaukee, WI
Rhabdomyosarcoma, the commonest soft tissue sarcoma in chil-
dren is initially chemosensitive with cures in 70%, but 5 year survival
for relapsed patients is 15–20% and only 5% for those with alveolar/
undifferentiated subtypes. Since autologous stem cell transplanta-
tion (ASCT) is not clearly defined for this disease, we describe out-
comes of 62 patients who received ASCT from 1989–2003 and
reported to CIBMTR. Pathology was confirmed through review of
reports for all cases. Transplant related mortality (TRM), progres-
sion-free survival (PFS) and overall survival (OS) were evaluated.
We also compared subgroups: poor risk histology (alveolar/undiffer-
entiated, n5 34) vs good risk (embryonal/botryoid, n5 21); patients
in 1st remission (REM1, n5 38) vs patients who relapsed (REL, n5
21); those presenting with metastases (n5 39) vs those without (n5
19); patients with poor risk histology who were in REM1 (n5 20) vs
REL (n5 12) and those with good risk histology who were in REM1
(n5 13) vs REL (n5 8). For the entire cohort, 73% were\20 yrs in
age, 52% were male, 39% presented with bulk .5cm, and 63% had
metastasis at diagnosis. Fifty percent had alveolar histology, 32%
embryonal subtype, 67% were in REM1, and 92% were chemosen-
sitive at ASCT. The conditioning regimens included melphalan in
53% and etoposide in 67%. There were no differences in the remis-
sion status at ASCT (63% vs 62% in REM1; p5 0.9) or median time
from diagnosis to ASCT (p 5 0.7) for those with good vs poor risk
histology. Patients with poor risk histology were more likely to
have marrow involved at diagnosis (44 vs 14%;p5 0.2), a CR to pri-
mary therapy (53% vs 26%;p 5 0.1) and being in a CR at ASCT
(70% vs 48%;p 5 0.2). For the entire group, the TRM at 1 year
was 5% (95% CI, 1–12); the 5 year PFS and OS were 29% (95%
CI, 18–41) and 32%(95% CI, 21–44) respectively. There were no
significant difference in 5 year PFS and OS between: those with
poor risk vs good risk histology (p5 0.6;p5 0.9), those transplanted
in REM1 vs REL (36% vs 29%;p5 0.5), those with poor risk histol-
ogy transplanted in REM1 vs REL (34% vs 33%;p 5 0.9), or those
with good risk histology transplanted in REM1 vs REL (38% vs
25%;p 5 0.2). These data indicate that ASCT for this disease are
typically done for patients with chemosensitive disease and suggest
that when performed after relapse, long-term survival is seen in ap-
proximately 1/3, seemingly better than previous reports of standard
dose salvage for those with alveolar/undifferentiated histologies.229
DEPLETION OF CD4 T CELLS LEADS TO INCREASED TUMOR IMMUNITY
AFTER HSCT IMMUNOTHERAPY BUT RESULTS IN LOSS OF MEMORY
Jing, W., Johnson, B.D. Medical College of Wisconsin, Milwaukee, WI
High-risk neuroblastoma is a clinically challenging disease. We
have demonstrated that established neuroblastoma can be eliminated
in a murine model by using a multi-faceted immunotherapeutic ap-
proach involving syngeneic hematopoietic stem cell transplantation
(HSCT), T cell transfer (cellular immunotherapy), and tumor vacci-
nation. One surprising finding in these experiments was that while
depletion of CD4 T cells resulted in decreased anti-tumor immunity
in mice given naı¨ve T cells as cellular immunotherapy, if the trans-
ferred T cells were pre-sensitized to tumor antigens (i.e., from
tumor-vaccinated donors) CD4 depletion resulted in increased
anti-tumor immunity. The increased anti-tumor efficacy in these
CD4-depleted hosts was accompanied by: (a) more vigorous prolif-
eration of CD8 cells in the spleens and tumor-draining lymph nodes
as observed in CFSE-labeling studies, (b) elevated percentages of
CD8 T cells with a CD62L-CD441 effector phenotype, (c) elevated
frequencies and absolute numbers of splenic tumor-reactive (IFN-g-
producing) CD8 cells, and (d) more robust tumor infiltration by
CD8 cells. However, development of long-term tumor immunity
(memory) was severely compromised in these CD4-depleted hosts,
as reflected by inability to resist a tumor re-challenge and diminished
in vitro CD8 recall responses. This loss of memory occurred even
though the adoptively transferred CD8 T cells were from donors
that had been vaccinated in the presence of CD4 cells, indicating
